Plasma cell leukemia: from biology to treatment
Jazyk angličtina Země Velká Británie, Anglie Médium print-electronic
Typ dokumentu časopisecké články, práce podpořená grantem, přehledy
PubMed
25778450
DOI
10.1111/ejh.12533
Knihovny.cz E-zdroje
- Klíčová slova
- bone marrow transplantation, bortezomib, multiple myeloma, plasma cell leukemia,
- MeSH
- analýza přežití MeSH
- autologní transplantace MeSH
- bortezomib terapeutické užití MeSH
- CD antigeny genetika metabolismus MeSH
- chromozomální aberace * MeSH
- exprese genu MeSH
- homologní transplantace MeSH
- indukční chemoterapie metody MeSH
- lidé MeSH
- mnohočetný myelom genetika mortalita patologie terapie MeSH
- plazmatické buňky patologie MeSH
- plazmocelulární leukemie genetika mortalita patologie terapie MeSH
- prognóza MeSH
- progrese nemoci MeSH
- protokoly antitumorózní kombinované chemoterapie aplikace a dávkování MeSH
- transplantace kmenových buněk * MeSH
- Check Tag
- lidé MeSH
- Publikační typ
- časopisecké články MeSH
- práce podpořená grantem MeSH
- přehledy MeSH
- Názvy látek
- bortezomib MeSH
- CD antigeny MeSH
Plasma cell leukemia (PCL) is a very aggressive and rare form of malignant monoclonal gammopathy characterized by the presence of plasmocytes in peripheral blood. It is classified as primary PCL occuring 'de novo', or as secondary PCL in patients with relapsed/refractory multiple myeloma. Primary PCL is a distinct clinicopathological entity from myeloma with different cytogenetic abnormalities and molecular findings, which are usually found only in advanced multiple myeloma. The clinical course is aggressive with short remissions and reduced overall survival. The diagnostic criteria are based on the percentage (>20%) and absolute number (2 × 10(9) /L) of plasma cells in peripheral blood. After establishing diagnosis, induction therapy should begin promptly which is aimed to rapid disease control and to minimize the risk of early death. Intensive chemotherapy regimens and bortezomib-based regimens, followed by high-dose therapy with autologous stem cell transplantation, are recommended. Allogeneic transplantation can be considered in younger patients. This article reviews recent knowledge of this hematological malignancy that is associated with a very poor prognosis.
University Hospital Brno Department of Clinical Haematology Brno Czech Republic
University Hospital Ostrava Department of Haematooncology Ostrava Czech Republic
University of Ostrava Faculty of Medicine Ostrava Czech Republic
Citace poskytuje Crossref.org
More Than 2% of Circulating Tumor Plasma Cells Defines Plasma Cell Leukemia-Like Multiple Myeloma
Plasma Cell Leukemia - Facts and Controversies: More Questions than Answers?
